Shots:
- The P-II (COMPASSION-03/AK104-201) trial assessed cadonilimab in pts with recurrent or metastatic CC who have failed prior Pt-based CT, showing mOS of 17.5mos. in pts regardless of PD-L1 expression, with18 & 24mos. OS rates of 47.8% & 40.9%, respectively
- Updated data with 26.5mos. mFU showed that among 99 efficacy-evaluable pts achieving CR, mOS & PFS were not reached, with a 24mos. OS rate of 100% & a 12mos. PFS rate of 84.6%
- In pts achieving PR, mOS was not reached with a 24mos. OS rate of 63%, while mPFS was 11.17mos. with a 12mos. PFS rate of 47.3%; mTTR was similar in CR (1.84mos.) & PR groups (1.87mos.), but mDoR was longer & not reached in CR pts
Ref: PRnewswire | Image: Akeso | Press Release
Related News: Akeso Receives NMPA Approval to Initiate P-II Trials of AK139 Across Seven Indications
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
